Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

A natural CCL5/RANTES variant antagonist for CCR1 and CCR3.

Capoulade-Métay C, Ayouba A, Kfutwah A, Lole K, Pêtres S, Dudoit Y, Deterre P, Menu E, Barré-Sinoussi F, Debré P, Theodorou I.

Immunogenetics. 2006 Jul;58(7):533-41. Epub 2006 Jun 22.

PMID:
16791620
2.

Differential activation of CC chemokine receptors by AOP-RANTES.

Elsner J, Mack M, Brühl H, Dulkys Y, Kimmig D, Simmons G, Clapham PR, Schlöndorff D, Kapp A, Wells TN, Proudfoot AE.

J Biol Chem. 2000 Mar 17;275(11):7787-94.

3.

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.

Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Schröder JM, Power CA, Wells TN.

J Biol Chem. 1999 Nov 5;274(45):32478-85.

4.

Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3.

Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, Coyle AJ, Nibbs RJ, Graham G, Offord RE, Wells TN.

J Immunol. 2003 Nov 15;171(10):5498-506.

5.

A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.

Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE.

J Leukoc Biol. 2001 Jun;69(6):977-85.

PMID:
11404385
6.

The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3.

Elsner J, Petering H, Höchstetter R, Kimmig D, Wells TN, Kapp A, Proudfoot AE.

Eur J Immunol. 1997 Nov;27(11):2892-8.

PMID:
9394815
7.

Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis.

Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, Teixeira MM, Lannes-Vieira J.

Circulation. 2004 Sep 14;110(11):1443-9. Epub 2004 Aug 30.

8.

Structural and functional analysis of the RANTES-glycosaminoglycans interactions.

Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C.

Biochemistry. 2001 May 29;40(21):6303-18.

PMID:
11371192
9.

Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5.

Pakianathan DR, Kuta EG, Artis DR, Skelton NJ, Hébert CA.

Biochemistry. 1997 Aug 12;36(32):9642-8.

PMID:
9289016
10.

The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.

Blanpain C, Doranz BJ, Bondue A, Govaerts C, De Leener A, Vassart G, Doms RW, Proudfoot A, Parmentier M.

J Biol Chem. 2003 Feb 14;278(7):5179-87. Epub 2002 Dec 3.

11.

Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage.

Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA.

J Exp Med. 1997 Dec 1;186(11):1865-72.

12.

I-TAC/CXCL11 is a natural antagonist for CCR5.

Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B.

J Leukoc Biol. 2004 Sep;76(3):701-8. Epub 2004 Jun 3.

PMID:
15178708
13.

Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium.

Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C.

Blood. 2003 Sep 15;102(6):1985-8. Epub 2003 May 22.

14.

Aminooxypentane-RANTES induces CCR3 activation and internalization of CCR3 from the surface of human eosinophils.

Elsner J, Dulkys Y, Kimmig D, Wells TN, Proudfoot AE, Kapp A.

Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):227-9.

PMID:
11306977
15.

Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor.

Struyf S, De Meester I, Scharpé S, Lenaerts JP, Menten P, Wang JM, Proost P, Van Damme J.

Eur J Immunol. 1998 Apr;28(4):1262-71.

16.

Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).

Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE.

J Med Virol. 2004 Jun;73(2):300-8.

PMID:
15122808
17.

C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap.

Nibbs RJ, Salcedo TW, Campbell JD, Yao XT, Li Y, Nardelli B, Olsen HS, Morris TS, Proudfoot AE, Patel VP, Graham GJ.

J Immunol. 2000 Feb 1;164(3):1488-97.

18.

The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.

Manns J, Rieder S, Escher S, Eilers B, Forssmann WG, Elsner J, Forssmann U.

Allergy. 2007 Jan;62(1):17-24.

19.
20.

Discovery of a novel CCR3 selective antagonist.

Naya A, Kobayashi K, Ishikawa M, Ohwaki K, Saeki T, Noguchi K, Ohtake N.

Bioorg Med Chem Lett. 2001 May 7;11(9):1219-23.

PMID:
11354381

Supplemental Content

Support Center